Implementing Sample Pooling and Aliquoting Techniques in Clinical Trials Under Regulatory Oversight

Introduction: Why Sample Pooling and Aliquoting Require Stringent Control

In large-scale clinical trials, efficient sample management is essential to minimize waste, improve throughput, and ensure timely analysis. Sample pooling and aliquoting are two widely used practices in bioanalytical laboratories for optimizing resources. However, both processes come with regulatory risks, particularly when poorly documented or improperly executed.

Regulatory authorities such as the FDA, EMA, and agencies under ICH guidance require detailed procedures and validations for pooling or aliquoting biological samples. This article provides a regulatory-compliant roadmap for implementing pooling and aliquoting techniques in clinical research, with focus on method validation, SOP development, risk mitigation, and CAPA planning.

What is Sample Pooling?

Sample pooling refers to combining biological specimens from multiple sources (e.g., different time points or subjects) into a single analytical run. It is often used for:

• Analyzing low-volume or rare samples
• Screening for analyte presence
• Quality control during method validation
• Retrospective PK assessments

Types of Pooling:

• Intrasubject pooling: Combining samples from the same subject
• Intersubject pooling: Combining samples across subjects (usually blinded)
• Matrix pool validation: Combining blank matrix samples for method development

What is Aliquoting?

Aliquoting is the process of dividing a larger biological sample into multiple smaller volumes (aliquots), each used for specific analytical procedures. This prevents repeated freeze-thaw cycles, reduces degradation risk, and facilitates storage logistics.

Common Practices for Aliquoting:

• Performing within 30 minutes of centrifugation
• Using pre-labeled, barcoded cryovials
• Documenting volume, time, analyst, and storage location in LIMS
• Ensuring aliquot traceability to original sample ID

Regulatory Considerations: FDA and EMA Expectations

While pooling and aliquoting are not explicitly banned, regulators mandate that such practices must:

• Be pre-specified in the study protocol or SAP (Statistical Analysis Plan)
• Be justified scientifically with documented rationale
• Maintain subject traceability and integrity of study blinding
• Be supported by validation data for pooled matrices
• Be governed by SOPs, with deviations recorded and investigated

In the 2021 FDA BIMO (Bioresearch Monitoring) inspection summary, several findings were issued for lack of validation for pooled matrices and undocumented aliquoting procedures.

Reference: ClinicalTrials.gov

Validation Requirements for Pooled Samples

When pooling is used for method validation or study analysis, the bioanalytical method must be assessed for:

• Recovery and matrix effect in the pooled sample
• Assay sensitivity post-dilution
• Analyte stability in mixed matrices
• Bias introduced due to heterogeneity

The pooled sample must meet the same acceptance criteria for accuracy and precision as individual samples. A sample validation report should accompany the pooled data.

Example Acceptance Criteria:

Case Study: Deviations in Pooling Documentation During Oncology Trial

A Phase II oncology trial utilized intersubject plasma pooling for pre-dose biomarker screening. During sponsor audit, it was found that:

• Pooling was performed by lab personnel but not pre-specified in the protocol
• No method validation was performed on pooled matrix
• Sample IDs were not traceable to individual subjects

CAPA Measures:

• Protocol amended to restrict pooling only during validation phase
• Validation study initiated for pooled plasma matrix
• SOPs revised to mandate traceability in all pooling events
• Retraining conducted for all sample processing personnel

Best Practices for Aliquoting SOPs

• Define time limits from sample receipt to aliquoting (e.g., ≤30 minutes)
• Include equipment requirements such as pre-chilled racks, automated pipettes
• Specify labeling requirements including date, time, analyst initials
• Ensure LIMS integration for real-time traceability
• Implement double-check by QA or second analyst for high-risk samples

Oversight and Inspection Readiness

During sponsor and regulatory audits, the following documentation must be available:

• Validated SOPs for pooling and aliquoting
• Raw data showing pre- and post-pooling concentrations
• Chain of custody logs for pooled samples
• Justification documents for protocol-level pooling decisions
• Corrective actions and retraining records if deviation occurred

Conclusion

Sample pooling and aliquoting can optimize lab efficiency but must be executed within a tightly regulated framework to ensure compliance and data integrity. By integrating pooling into protocol design, performing matrix-specific validation, ensuring traceability, and maintaining robust SOPs, sponsors and laboratories can prevent CAPAs, protect subjects, and withstand FDA/EMA inspections.

Managing Analyte Stability and Freeze-Thaw Cycles for Regulatory-Ready Bioanalysis

Introduction: The Risk of Analyte Degradation in Clinical Trials

Stability of analytes in clinical trial samples is critical for producing scientifically reliable and regulatory-compliant data. Analyte degradation due to temperature fluctuations, prolonged exposure, or excessive freeze-thaw cycles can lead to variability in pharmacokinetic (PK) or biomarker data. This not only jeopardizes study outcomes but can also attract regulatory observations during inspections.

Regulatory bodies including FDA, EMA, and the newly harmonized ICH M10 guidance have emphasized the importance of robust analyte stability data during method validation. Risk-based oversight strategies must be embedded into every phase of sample lifecycle management — from collection to final reporting.

Key Parameters of Analyte Stability

Stability testing is required under various storage and handling conditions. The table below summarizes the different types of analyte stability evaluations:

Case Study 1: Freeze-Thaw Instability of Cytokine Analytes

In a global inflammation study, the CRO used a multiplex assay to quantify IL-6, TNF-α, and other cytokines. During method validation, the team identified significant degradation (>20%) in IL-6 after two freeze-thaw cycles, rendering the method non-compliant.

CAPA Implementation:

• Limited allowable freeze-thaw to 1 cycle via SOP revision
• Added immediate analysis requirement after first thaw
• Labeled samples with “Do Not Re-freeze” stickers
• Implemented real-time deviation tracking for re-thawed samples
• Re-trained staff on biomarker sensitivity

These actions ensured stability compliance while minimizing impact on data integrity and subject eligibility criteria.

ICH M10 and Regulatory Expectations

The ICH M10 guideline mandates detailed stability evaluation as part of the method validation package. The following are key expectations:

• Freeze-thaw studies should be performed in matrix at intended concentration range
• Stability data should support the entire duration of sample storage
• All deviations from defined stability conditions must trigger revalidation or investigation
• Stability must be proven in incurred sample matrices if available

Risk-Based Oversight Strategy for Analyte Stability

Instead of a one-size-fits-all SOP, modern quality systems apply risk-based stratification. Here’s how:

• Low-risk: Small molecules with known chemical stability — minimal cycles allowed
• Medium-risk: Protein analytes in plasma/serum — validate up to 3 cycles, real-time monitoring
• High-risk: Biomarkers, RNA, cytokines — single-use aliquots, cold-chain verified transport

Sample Aliquoting to Minimize Freeze-Thaw Events

Aliquoting is a key preventive strategy. By dividing biological samples into multiple cryovials upon initial processing, labs can avoid thawing the entire volume for each analysis. Recommendations:

• Use pre-labeled 2 mL cryovials
• Document aliquot IDs in LIMS linked to subject/sample ID
• Assign maximum allowable thaw count in SOP (typically 1–2)
• Use barcode or RFID-based tracking for thaw history

Case Study 2: Temperature Excursion During Shipping

A Phase I trial in Eastern Europe experienced a courier delay, resulting in 30 serum samples exposed to 10°C for over 12 hours. The storage SOP did not include excursion analysis criteria.

CAPA Strategy:

• Retrospective stability testing at 10°C performed for serum matrix
• Excursion acceptance criteria defined and embedded in SOP
• Courier agreements revised to include thermal logger validation
• Temperature probes now mandatory in all shipments

External Resource

For additional guidance on stability testing and method validation, refer to the Australian New Zealand Clinical Trials Registry which includes regional guidance on analyte handling and reporting.

Conclusion

Analyte stability and freeze-thaw resilience are foundational components of method validation and data reliability. Risk-based oversight, robust SOPs, CAPA preparedness, and staff training ensure trial integrity and inspection readiness. By proactively addressing degradation risks and implementing technology-driven tracking, clinical labs and sponsors can ensure regulatory compliance and safeguard patient data in complex global studies.